Guggenheim initiated coverage of Avalo Therapeutics (AVTX) with a Buy rating and $50 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTX:
- Avalo Therapeutics management to meet with Piper Sandler
- Avalo Therapeutics management to meet with Cantor Fitzgerald
- De-Risked LOTUS Phase 2 Design and Monthly Dosing Support Reiterated Buy on Avalo Therapeutics
- Avalo Therapeutics Highlights AVTX-009 Progress in HS
- Avalo Therapeutics files $750M mixed securities shelf